[go: up one dir, main page]

EP4249505A4 - Long-acting glucagon derivative - Google Patents

Long-acting glucagon derivative Download PDF

Info

Publication number
EP4249505A4
EP4249505A4 EP20966375.6A EP20966375A EP4249505A4 EP 4249505 A4 EP4249505 A4 EP 4249505A4 EP 20966375 A EP20966375 A EP 20966375A EP 4249505 A4 EP4249505 A4 EP 4249505A4
Authority
EP
European Patent Office
Prior art keywords
long
glucagon derivative
acting glucagon
acting
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20966375.6A
Other languages
German (de)
French (fr)
Other versions
EP4249505A1 (en
Inventor
Yanshan Huang
Sheng NI
Jinqiang XIA
Mingyue ZHU
Chen Fang
Peng Sun
Hang Zhao
Bingyong XU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Heze Pharmaceutical Technology Co Ltd
Zhejiang Doer Biologics Co Ltd
Original Assignee
Zhejiang Heze Pharmaceutical Technology Co Ltd
Zhejiang Doer Biologics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Heze Pharmaceutical Technology Co Ltd, Zhejiang Doer Biologics Co Ltd filed Critical Zhejiang Heze Pharmaceutical Technology Co Ltd
Publication of EP4249505A1 publication Critical patent/EP4249505A1/en
Publication of EP4249505A4 publication Critical patent/EP4249505A4/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/605Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP20966375.6A 2020-12-23 2020-12-23 Long-acting glucagon derivative Pending EP4249505A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2020/138597 WO2022133797A1 (en) 2020-12-23 2020-12-23 Long-acting glucagon derivative

Publications (2)

Publication Number Publication Date
EP4249505A1 EP4249505A1 (en) 2023-09-27
EP4249505A4 true EP4249505A4 (en) 2024-08-21

Family

ID=82158584

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20966375.6A Pending EP4249505A4 (en) 2020-12-23 2020-12-23 Long-acting glucagon derivative

Country Status (8)

Country Link
US (1) US20240059752A1 (en)
EP (1) EP4249505A4 (en)
JP (1) JP7573760B2 (en)
KR (1) KR20230126712A (en)
CN (2) CN118184764A (en)
AU (1) AU2020483085B2 (en)
CA (1) CA3205610A1 (en)
WO (1) WO2022133797A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116710462A (en) 2021-01-20 2023-09-05 维京治疗公司 Compositions and methods for treating metabolic disorders and liver diseases
CN118265720A (en) 2021-09-15 2024-06-28 维京治疗公司 Compositions and methods for treating metabolic disorders and liver diseases
CN117586374B (en) * 2023-10-07 2024-11-29 深圳湾实验室 GLP-1R/GIPR/GCGR triple agonist analogs and their uses
CN119285747A (en) * 2024-10-14 2025-01-10 晨伫(杭州)生物科技有限责任公司 A GLP-1 derivative and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013192129A1 (en) * 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Glucagon analogs exhibiting gip receptor activity
WO2019101036A1 (en) * 2017-11-24 2019-05-31 浙江道尔生物科技有限公司 Multiple-active protein for treating metabolic diseases
WO2020228360A1 (en) * 2019-05-16 2020-11-19 浙江道尔生物科技有限公司 Fusion protein for treatment of metabolic disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2512503A4 (en) 2009-12-18 2013-08-21 Univ Indiana Res & Tech Corp GLUCAGON / GLP-I RECEPTOR CO-AGONISTS
MX2013006304A (en) * 2010-12-22 2013-07-02 Univ Indiana Res & Tech Corp GLUCAGON ANALOGS THAT DISPLAY ACTIVITY OF THE GIP RECEIVER.
US8729017B2 (en) 2011-06-22 2014-05-20 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US10100097B2 (en) * 2012-05-03 2018-10-16 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
CA2877127A1 (en) 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Analogs of glucagon exhibiting gip receptor activity
KR102310392B1 (en) * 2013-11-06 2021-10-13 질랜드 파마 에이/에스 Glucagon-glp-1-gip triple agonist compounds
CN115304666B (en) * 2017-11-24 2025-09-19 浙江道尔生物科技有限公司 Glucagon analogues for the treatment of metabolic disorders
CN111349155B (en) * 2018-12-24 2022-04-05 浙江和泽医药科技股份有限公司 Glucagon analogue and preparation method and application thereof
US20220127323A1 (en) * 2019-01-07 2022-04-28 Vitalixir (Beijing) Co., Ltd Novel polypeptide and therapeutic uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013192129A1 (en) * 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Glucagon analogs exhibiting gip receptor activity
WO2019101036A1 (en) * 2017-11-24 2019-05-31 浙江道尔生物科技有限公司 Multiple-active protein for treating metabolic diseases
WO2020228360A1 (en) * 2019-05-16 2020-11-19 浙江道尔生物科技有限公司 Fusion protein for treatment of metabolic disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2022133797A1 *

Also Published As

Publication number Publication date
WO2022133797A1 (en) 2022-06-30
EP4249505A1 (en) 2023-09-27
CN114981294A (en) 2022-08-30
AU2020483085A1 (en) 2023-07-06
CN114981294B (en) 2024-04-26
CA3205610A1 (en) 2022-06-30
JP2023552500A (en) 2023-12-15
CN118184764A (en) 2024-06-14
JP7573760B2 (en) 2024-10-25
US20240059752A1 (en) 2024-02-22
AU2020483085B2 (en) 2024-03-07
AU2020483085A9 (en) 2025-04-10
KR20230126712A (en) 2023-08-30

Similar Documents

Publication Publication Date Title
EP4249505A4 (en) Long-acting glucagon derivative
EP4086277A4 (en) Long-acting glp-1 compound
EP4086279A4 (en) Insulin derivative
EP3741756A4 (en) Pyridone-pyrimidine derivative acting as krasg12c mutein inhibitor
EP4116298A4 (en) Piperidinedione derivative
EP3866765A4 (en) Injectable long-acting naltrexone microparticle compositions
EP4450502A4 (en) Azaindole derivative inhibiting h-pgds
EP4138783A4 (en) Long-acting bupivacaine microsphere formulations
EP4347973A4 (en) Improved prop assemblies
HK40115534A (en) Long-acting glp-1 compound
HK40094144A (en) Long-acting formulations
HK40099053A (en) Long-acting dnase
HK40101507A (en) Borono-phenylalanine derivative
HK40094126A (en) 5-heteroaryl-1h-pyrazol-3-amine derivative
HK40089693B (en) Dimethylsulfoximine derivative
HK40089693A (en) Dimethylsulfoximine derivative
HK40109784A (en) Insulin derivative
HK40102509A (en) Glucagon like peptide compounds
HK40119151A (en) Dihydro-oxazol derivative compounds
HK40070502B (en) Insulin derivative
AU2020900461A0 (en) Centraliser
HK40109423A (en) New aryl-pyrido-pyrimidin-one derivatives
HK40104845A (en) Camptothecin derivatives
HK40093036A (en) New thiazolopyrimidinone derivatives
HK40094396A (en) New thienopyrimidinone derivatives

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230622

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20240723

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 3/10 20060101ALI20240717BHEP

Ipc: A61P 3/06 20060101ALI20240717BHEP

Ipc: A61P 3/04 20060101ALI20240717BHEP

Ipc: A61P 1/16 20060101ALI20240717BHEP

Ipc: C07K 1/04 20060101ALI20240717BHEP

Ipc: A61K 38/26 20060101ALI20240717BHEP

Ipc: C07K 14/605 20060101AFI20240717BHEP